Oral Bacteria and Colorectal Pathology

Document Type : Review Article

Author

Burdwan Dental College & Hospital, Burdwan, India

Abstract

Context- The oral cavity and the colon, though part of the alimentary tract are distantly located anatomically and hence are colonized by totally divergent microbes. The mouth is affected by several pathologies and so is the colon. So it is quite natural to investigate the probable connection between poor oral health and colorectal pathologies.

Evidence acquisition- This article is a small attempt to identify the oral microbiota, how they translocate to the colon-rectum area and then how do they create pathology there. Pubmed indexed journals relating to this topic were screened and shortlisted to construct this article.

Results- The organisms generally responsible for the oral diseases, namely Fusobacterium nucleatum and Porphyromonas gingivalis among others have been found in colon disorders resulting in intestinal dysbiosis and ultimately leading to colorectal cancer.

Conclusions-
If the disease pathogenesis is well understood, then it will open new ways on how to prevent or treat colorectal pathologies. However further studies are needed in this arena.

Keywords


1)    Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-14.
2)    Li K, Bihan M, Yooseph S, Methé BA. Analyses of the microbial diversity across the human microbiome. PLoS ONE 2012; 7:e32118.
3)    Escapa IF, Chen T, Huang Y, Gajare P, Dewhirst FE, Lemon KP. New insights into human nostril microbiome from the expanded Human Oral Microbiome Database (eHOMD): A resource for the microbiome of the human aerodigestive tract. MSystems 2018;3
4)    Griffen AL, Beall CJ, Campbell JH, Firestone ND, Kumar PS, Yang ZK et al. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. ISME J. 2012; 6:1176-85.
5)    Matarazzo F, Ribeiro AC, Feres M, Faveri M, Mayer MPA. Diversity and quantitative analysis of Archaea in aggressive periodontitis and periodontally healthy subjects. J. Clin. Periodontol. 2011; 38:621-77.
6)    Vartoukian SR, Palmer RM, Wade WG. Diversity and morphology of members of the phylum “synergistetes” in periodontal health and disease. Appl. Environ. Microbiol. 2009; 75:3777-86.
7)    Haubek D. The highly leukotoxic JP2 clone of Aggregatibacter actinomycetemcomitans: Evolutionary aspects, epidemiology and etiological role in aggressive periodontitis. APMIS 2010; 118.
8)    Costalonga M, Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and caries. Immunol. Lett. 2014; 162:22–38.
9)    Koo H, Bowen WH. Candida albicans and Streptococcus mutans: A potential synergistic alliance to cause virulent tooth decay in children. Future Microbiol. 2014; 9:1295-7.
10)     Wang L, Ganly I. The oral microbiome and oral cancer. Clin. Lab. Med. 2014; 34:711-9.
11)     Pushalkar S, Ji X, Li Y, Estilo C, Yegnanarayana R, Singh B, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012; 12:144.
12)     Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res. 2017; 77:6777-87.
13)     Fitzpatrick SG, Katz J. The association between periodontal disease and cancer: A review of the literature. J. Dent. 2010; 38:83-95.
14)     Michaud DS, Fu Z, Shi J, Chung M. Periodontal disease, tooth loss and cancer risk. Epidemiol. Rev. 2017; 39:49-58.
15)     Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012; 13:489(7415):242-9.
16)     Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol. 2013; 6(1):53-68.
17)     Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013; 66(2):462-70.
18)     Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359-86.
19)     Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis. 2011; 17(1):396-409.
20)     Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338(6103):120-3.
21)     Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012; 7(6):e39743.
22)     Fukuda M, Komiyama Y, Mitsuyama K, Andoh A, Aoyama T, Matsumoto Y et al. Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J Clin Biochem Nutr. 2011; 49(1):57-61.
23)     Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22(2):299-306.
24)     Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012; 10(8):575-82.
25)     Maekawa T, Krauss JL, Abe T, Jotwani R, Triantafilou M, Triantafilou K et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. 2014; 15(6):768-78.
26)     Zenobia C, Hajishengallis G. Porphyromonas gingivalis virulence factors involved in subversion of leukocytes and microbial dysbiosis. Virulence. 2015; 6(3):236-43.
27)     Kato T, Yamazaki K, Nakajima M, Date Y, Kikuchi J, Hase K, et al. Oral Administration of Porphyromonas gingivalis Alters the Gut Microbiome and Serum Metabolome. mSphere. 2018; 3(5).
28)     Sato K, Takahashi N, Kato T, Matsuda Y, Yokoji M, Yamada M, et al. Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. Sci Rep. 2017; 7(1):6955.
29)     Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513(7516):59-64.
30)     Lourenςo TGB, Spencer SJ, Alm EJ, Colombo APV. Defining the gut microbiota in individuals with periodontal diseases: an exploratory study. J Oral Microbiol. 2018; 10(1):1487741.
31)     Bajaj JS, Matin P, White MB, Fagan A, Deeb JG, Acharya C, et al. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018; 315(5):G824-37.
32)     Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015; 6:8727.
33)     Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, et al. Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. Cancer Epidemiol Biomarkers Prev. 2017; 26(1):85-94.
34)     Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, et al. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin Cancer Res. 2017; 23(8):2061-70.
35)     Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017; 66(4):633-43.
36)     Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2018; 67(8):1454-63.
37)     Momen-Heravi F, Babic A, Tworoger SS, Zhang L, Wu K, Smith-Warner SA et al. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses’ Health Study. Int. J. Cancer. 2017; 140:646-52.
38)     Yang Y, Cai Q, Shu XO, Steinwandel MD, Blot WJ, Zheng W, et al. Prospective study of oral microbiome and colorectal cancer risk in low-income and African American populations. Int J Cancer. 2019; 144(10):2381-9.
39)     Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22(2):292-8.
40)     Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014; 33(8):1381-90.
41)     Mima K, Cao Y, Chan AT, Qian ZR, Nowak JA, Masugi Y, et al. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016; 7(11):e200.
42)     Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011; 13(2):25-36.
43)     Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013; 105(24):1907-11.
44)     Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206.
45)     Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014; 74(5):1311-8.
46)     Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015; 6:20.
47)     Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015; 137(6):1258-68.
48)     Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer. 2013; 119(17):3140-7.
49)     Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012; 13(6):R42.
50)     Li B, Ge Y, Cheng L, Zeng B, Yu J, Peng X, et al. Oral bacteria colonize and compete with gut microbiota in gnotobiotic mice. Int J Oral Sci. 2019; 11(1):10.
51)     Nakajima M, Arimatsu K, Kato T, Matsuda Y, Minagawa T, Takahashi N, et al. Oral Administration of P. gingivalis Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. PLoS One. 2015; 10(7):e0134234.
52)     Saygun I, Nizam N, Keskiner I, Bal V, Kubar A, Aç─▒kel C, et al. Salivary infectious agents and periodontal disease status. J Periodontal Res. 2011; 46(2):235-9.
53)     Parahitiyawa NB, Jin LJ, Leung WK, Yam WC, Samaranayake LP. Microbiology of odontogenic bacteremia: beyond endocarditis. Clin Microbiol Rev. 2009; 22(1):46-64.
54)     Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015; 15(1):30-44.